Suraksha Diagnostic launches genomics lab in Kolkata, aims to become Eastern India’s precision diagnostics leader
Find out how Suraksha Diagnostic’s ₹22 crore genomics lab launch in Kolkata could redefine cancer, prenatal, and rare disease testing in Eastern India.
Why is Suraksha Diagnostic investing ₹68 crore into genomics testing and what could it mean for Indian precision medicine?
Kolkata-headquartered Suraksha Diagnostic Limited (NSE: SURAKSHA, BSE: 544293) has inaugurated Eastern India’s largest state-of-the-art genomics laboratory on July 4, 2025, with an initial investment of ₹22 crore and an additional ₹46 crore commitment over the next two years. The lab’s launch event, attended by prominent medical professionals including Professor Sukumar Mukherjee, marks a pivotal moment in India’s diagnostic landscape, particularly for the Eastern and North-Eastern regions.
Located in West Bengal’s fast-developing healthcare corridor, this new genomics facility will serve as a key strategic node in Suraksha Diagnostic’s broader ambition to dominate precision diagnostics in India. From prenatal screenings to onco-genomic profiling, the lab is designed to handle a full range of next-generation sequencing (NGS), cytogenetic, and microarray-based diagnostic services.
With this investment, Suraksha Diagnostic is positioning itself as a genomics-forward diagnostics chain aligned with global healthcare trends, while reinforcing its post-IPO growth strategy following its December 2024 listing.

What capabilities does Suraksha’s new genomics lab offer and how do they compare to global standards?
The genomics lab integrates a full suite of advanced platforms including Cytogenetics, Sanger Sequencing, Chromosomal Microarray, and multiple Next-Generation Sequencers (NGS). It is also equipped with Fluorescent In Situ Hybridization (FISH) technology, allowing for high-resolution visualization of chromosomal structures. These technologies enable broad-spectrum testing from large-scale structural chromosomal anomalies to minute gene-level variations.
Initial clinical applications target prenatal, reproductive, paediatric, and oncology segments. Suraksha’s prenatal diagnostics program includes screening for Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. These services are bolstered by in-house genetic counselling—a critical differentiator in an underserved regional market.
In oncology, the diagnostics network has rolled out comprehensive hereditary cancer testing panels. These panels support both germline and somatic mutation analysis across breast, ovarian, and colorectal cancers, enabling oncologists to prescribe targeted treatments based on actionable genomic insights. With clinicians increasingly relying on genetic stratification for cancer treatment decisions, Suraksha Diagnostic’s lab positions itself as one of the few facilities in Eastern India capable of delivering high-precision onco-genomic diagnostics at scale.
How does this genomics initiative align with broader growth and investment trends at Suraksha Diagnostic?
The genomics push represents a natural extension of Suraksha Diagnostic’s post-IPO expansion plan. In December 2024, the diagnostics company successfully raised ₹846.25 crore through its IPO, which was subscribed 1.27 times. Institutional investors reportedly viewed the offering as a long-term bet on healthcare infrastructure development in Tier II and Tier III Indian cities, especially in diagnostics.
That optimism appears to have been validated in Suraksha’s FY25 financials. For the year ended March 31, 2025, the company reported ₹2,559.4 million in total income, up 15.2% year-on-year. EBITDA grew 15.6% to ₹850.9 million, while Profit After Tax surged 34% to ₹309.8 million, reflecting stronger margin performance across mature centres.
Despite external headwinds—such as the West Bengal doctors’ strike and regulatory frictions in cross-border sample movement with Bangladesh—the diagnostics firm added seven new centres during the year. More importantly, it moved into the genomic medicine space through the April 2025 acquisition of Fetomat Wellness Private Limited, a pregnancy care and prenatal diagnostics specialist. Suraksha now holds a 63% equity stake in Fetomat, making it a strategic subsidiary.
According to executives, this acquisition created foundational synergies for the genomics lab initiative, particularly in prenatal genetics and reproductive health.
What are institutional investors saying about Suraksha’s genomics pivot and regional diagnostics expansion?
While there has been no formal analyst coverage post-inauguration, indirect cues from market sentiment and investor behavior around the IPO suggest strong confidence in Suraksha’s strategic pivot. Institutional investors appear particularly focused on three fronts: high-margin genomics diagnostics, regulatory moats in underserved regions, and the growing relevance of preventive care in Indian urban and semi-urban centers.
The diagnostic chain’s genomics rollout is well-aligned with global health trends. According to industry projections cited by Suraksha, the global genetic testing market stood at USD 38.77 billion in 2024 and is expected to reach USD 186.64 billion by 2035, growing at a CAGR of 22.5%. Against this backdrop, Suraksha’s ₹68 crore multi-phase genomics investment over the next two years may be viewed as a relatively conservative but targeted deployment of capital to capture early-mover advantages in Eastern India.
Analysts believe that the company’s ability to house high-throughput genomic sequencing technologies—traditionally limited to premier academic institutions or pan-India players like SRL or Thyrocare—will enhance its pricing power and clinician loyalty in regional hubs like Kolkata, Siliguri, Patna, and Guwahati.
How does Suraksha plan to scale its genomics vision nationally beyond Eastern India?
Suraksha Diagnostic’s genomics lab is not just a standalone facility but part of a broader multi-year strategy to embed genomics into routine clinical workflows across India. CEO and Joint Managing Director Ms. Ritu Mittal highlighted this long-term vision, stating that the company aims to become a premium, aspirational choice for families and clinicians seeking end-to-end genetic solutions in fetal, reproductive, paediatric, and cancer care.
Chairman Dr. Somnath Chatterjee framed the genomics lab as central to Suraksha’s mission of delivering predictive analytics and early diagnosis through genome-driven science. By 2030, the diagnostics network envisions contributing to several national priorities including rare disease registries, newborn screening programs, and clinical research collaborations.
To that end, the diagnostics provider is likely to continue investing in R&D partnerships, academic collaborations, and possibly public-private health initiatives. With its AI-powered digital lab infrastructure and ISO/CAP/NABL-accredited network, Suraksha is well-positioned to operationalize genomics data across population health programs and clinical decision support.
What is the outlook for Suraksha Diagnostic in FY26 and beyond?
With 15–18 new diagnostic centres expected to be added in FY26, Suraksha is doubling down on both scale and specialization. Management anticipates improved operating leverage as these new centres mature, driving higher throughput and margin expansion. The genomics lab is expected to contribute meaningfully to revenue within two years, particularly as awareness and accessibility of genetic testing improve across India’s eastern corridor.
On the capital side, the ₹68 crore genomics investment is being executed in tranches, giving the diagnostics provider flexibility to calibrate rollout based on early clinical adoption and regulatory dynamics.
If genomics penetration in India tracks even a fraction of global trends, Suraksha’s integrated genomics and diagnostics model could set a new benchmark for regional diagnostic networks nationwide.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.